CRISPR-Validated Target Druggability for Small Molecule Drugs

CRISPR-Cas9 enables researchers to achieve a panoramic analysis of gene function in complex models such as human cells and organoids through the precise pairing of sgRNA and target DNA sequences (single-base level cutting accuracy). Its efficiency improvement is reflected in:

Whole genome screening innovation: Tools such as GeCKO library can scan tens of thousands of genes in a single experiment, such as the discovery of 12 core regulatory genes related to breast cancer metastasis;

Dynamic functional simulation: Through the dual modes of CRISPRa (activation) and CRISPRi (inhibition), simulate the gene dosage effect and reveal the temporal role of the target in disease progression;

Drug resistance reverse engineering: construct cell models carrying clinical mutations (such as EGFR T790M), predict drug failure mechanisms and design allosteric inhibitors.

CRISPR technology deeply affects the evaluation criteria from molecular mechanism to clinical transformation:

Target biological verification: distinguish the functional differences of targets in normal tissues and lesions through conditional gene knockout (such as Cre-loxP system) to reduce the risk of toxicity;

Multi-omics data fusion: integrate single-cell sequencing and protein interaction network to identify the "functional hotspot area" of the target and guide the design of small molecule binding pockets;

Quantification of synthetic lethal effect: use CRISPR double gene knockout library to calculate the target synergy index (CSI) and screen highly selective drug combinations.

Case 1: Development of KRAS G12C inhibitors

CRISPR screening found that SHP2 protein is a key synergistic factor of KRAS mutants, which promoted the combination therapy of SHP2 inhibitors (such as RMC-4630) and KRAS inhibitors into clinical phase II;

Case 2: BCL-2 anti-apoptotic protein inhibitors

CRISPR gain-of-function mutations revealed the phosphorylation site resistance mechanism of BCL-2, guiding the design of an optimized version of the allosteric inhibitor Venetoclax;

Case 3: Epigenetic target EZH2

CRISPR-Cas9-mediated histone methylation dynamic tracking technology verifies the epigenetic dependence of the EZH2 inhibitor Tazemetostat in lymphoma.

Current technical bottlenecks:

Delivery efficiency issues: The delivery efficiency of lipid nanoparticle (LNP) carriers in tissues outside the liver is less than 5%, which limits its application in solid tumor models;

Homology-directed repair (HDR) barriers: The HDR efficiency in mammalian cells is only 0.1%-5%, resulting in a low success rate of precise editing.

Innovative solutions:

Prime Editing technology: Through the fusion of reverse transcriptase and Cas9 protein, precise editing without DNA double-strand breaks is achieved, and the HDR efficiency is increased to 30%;

AAV capsid modification: Directed evolution screens AAV9 variants targeting neural cells to break through the blood-brain barrier delivery limitations.

Cross-dimensional integration strategy:

Virtual screening optimization: Based on the target conformational change data obtained by CRISPR, molecular dynamics models (such as Gaussian accelerated MD) are trained to predict changes in small molecule binding energy;

Organoid drug sensitivity testing: CRISPR-edited colon cancer organoids are tested in parallel with patient-derived xenograft models (PDX) to verify the tissue-specific toxicity of drugs;

AI-driven iteration: Using the massive functional genomic data generated by CRISPR screening, deep learning algorithms are trained to predict the multi-target effects of small molecules.